Pegasus Partners Ltd. Abb Vie Inc. Transaction History

Pegasus Partners Ltd.

$944 Million
Q1 2024

A detailed history of Pegasus Partners Ltd. transactions in Abb Vie Inc. stock. As of the latest transaction made, Pegasus Partners Ltd. holds 5,099 shares of ABBV stock, worth $856,886. This represents 0.1% of its overall portfolio holdings.

Number of Shares

5,099

Previous 5,010 1.78%

Holding current value

$856,886

Previous $776,000 19.59%

% of portfolio

0.1%

Previous 0.09%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	BUY	$159.82 - $182.1 $14,223 - $16,206	89 Added 1.78%	5,099 $928,000
Q4 2023 Feb 12, 2024	SELL	$137.6 - $154.97 $18,851 - $21,230	-137 Reduced 2.66%	5,010 $776,000
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $87,635 - $101,450	656 Added 14.61%	5,147 $767,000
Q2 2023 Aug 04, 2023	SELL	$132.51 - $164.9 $795 - $989	-6 Reduced 0.13%	4,491 $605,000
Q3 2022 Nov 10, 2022	SELL	$134.21 - $153.93 $92,873 - $106,519	-692 Reduced 13.34%	4,497 $604,000

Q2 2022 Aug 12, 2022	BUY	$137.62 - $174.96 $9,633 - $12,247	70 Added 1.37%	5,189 $795,000
Q1 2022 May 13, 2022	BUY	$131.98 - $163.75 $277,949 - $344,857	2,106 Added 69.9%	5,119 $830,000
Q4 2021 Feb 09, 2022	SELL	$107.43 - $135.93 $600,211 - $759,440	-5,587 Reduced 64.97%	3,013 $408,000
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $212 - $241	2 Added 0.02%	8,600 $928,000
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $315 - $351	3 Added 0.03%	8,598 $968,000
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $306 - $337	3 Added 0.03%	8,595 $930,000
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $241 - $326	3 Added 0.03%	8,592 $921,000
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $257 - $302	3 Added 0.03%	8,589 $752,000
Q2 2020 Aug 12, 2020	BUY	$73.37 - $98.18 $17,315 - $23,170	236 Added 2.83%	8,586 $843,000
Q1 2020 May 11, 2020	SELL	$64.5 - $97.79 $184,083 - $279,092	-2,854 Reduced 25.47%	8,350 $636,000
Q4 2019 Feb 12, 2020	SELL	$72.13 - $90.25 $111,729 - $139,797	-1,549 Reduced 12.15%	11,204 $992,000
Q3 2019 Oct 24, 2019	SELL	$62.98 - $75.72 $493,637 - $593,493	-7,838 Reduced 38.07%	12,753 $966,000
Q2 2019 Jul 30, 2019	SELL	$65.7 - $83.98 $170,031 - $217,340	-2,588 Reduced 11.17%	20,591 $1.5 Million
Q1 2019 May 13, 2019	BUY	$77.14 - $90.79 $439,003 - $516,685	5,691 Added 32.54%	23,179 $1.87 Million
Q4 2018 Feb 01, 2019	SELL	$77.85 - $96.01 $736,383 - $908,158	-9,459 Reduced 35.1%	17,488 $1.61 Million
Q3 2018 Nov 07, 2018	BUY	$88.91 - $98.84 $24,094 - $26,785	271 Added 1.02%	26,947 $2.55 Million
Q2 2018 Jul 27, 2018	BUY	$89.78 - $106.23 $173,814 - $205,661	1,936 Added 7.83%	26,676 $2.47 Million
Q1 2018 May 09, 2018	BUY	$92.01 - $123.21 $1.35 Million - $1.81 Million	14,690 Added 146.17%	24,740 $2.34 Million
Q4 2017 Feb 08, 2018	BUY	$89.56 - $98.21 $27,494 - $30,150	307 Added 3.15%	10,050 $972,000
Q3 2017 Nov 09, 2017	BUY	$69.85 - $89.22 $680,548 - $869,270	9,743	9,743 $866,000

Others Institutions Holding ABBV

# of Institutions

3,657

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $297B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pegasus Partners Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Pegasus Partners Ltd. with notifications on news.

Account

Pegasus Partners Ltd. Abb Vie Inc. Transaction History